Latest diabetes mellitus Stories

OULU, Finland, May 22, 2013 /PRNewswire/ -- JOT Automation, a global automation company, has delivered a novel manufacturing solution for Tandem Diabetes Care(R), Inc., which is used to manufacture a component of the t:slim(R) Insulin Pump. The partnership with Tandem Diabetes Care is part of JOT Automation's growth strategy to use its mass production know-how, originated from the telecom industry, to serve the needs of the leading life science manufacturers. The...

-- Studies Presented at ISPOR Meeting Underscore Potential Cost Savings for Improved Diabetes Control -- NEW ORLEANS, May 22, 2013 /PRNewswire/ -- Hemoglobin A1C levels increased over a four-year period for commercially-insured patients with Type 2 diabetes, while modest improvements in A1C control has been shown to improve health outcomes and can lead to substantial healthcare cost savings, according to two studies presented at the International Society for Pharmacoeconomics and...

GREENSBORO, N.C., May 22, 2013 /PRNewswire/ -- Author Risa Peets recently published a new book titled, "It's OK To Be Different" to educate children and parents about managing childhood or juvenile diabetes. Rising obesity rates and decreased access to healthy and affordable nutrition have caused Type I and Type II diabetes to reach epidemic levels for adults and children throughout the United States. Diabetes (both types) is related to how the body makes insulin and uses...

Extend Nutrition Snacks Creator Releases New Book on Insulin Pumps St. Louis, MO (PRWEB) May 21, 2013 Dr. Francine Kaufman, inventor of Extend Nutrition, recalls the first insulin pump she used with her patients in the 1980s: It weighed several pounds and was jokingly referred to as the “big blue brick.” For the most part, it could only be used in the hospital setting. The technology has advanced greatly in the 30 years since then, and the advantages are greater as well. The insulin...

INBalance Health Corporation, a company providing doctor-formulated, alternative food bar and supplement solutions to the Diabetic, Weight loss, and Non-Allergen Markets, attended a recent Trade Show in Shanghai, China. The Show served as the launch pad of their products to the International Market. (PRWEB) May 20, 2013 INBalance Health Corporation, a company providing doctor-formulated, alternative food bar and supplement solutions to the Diabetic, Weight loss, and Non-Allergen Markets,...

Optimal treatment of sleep apnea in patients with prediabetes improves blood sugar (glucose) levels and thus can reduce cardiometabolic risk, according to a study to be presented at the ATS 2013 International Conference in Philadelphia. "Sleep apnea, a condition associated with breathing disturbances during sleep is known to be associated with abnormalities in glucose metabolism, but whether treatment of sleep apnea has any beneficial effects on glucose metabolism is still under...

AbbVie presents results of Phase 2b studies NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and type 2 diabetes. SONAR is a large, multinational,...

BOSTON, May 20, 2013 /PRNewswire/ -- Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis in type 1 diabetic patients. The trial demonstrated that RM-131 significantly accelerates early gastric emptying and reduces upper gastrointestinal (GI) symptoms in type 1 diabetic patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2013...

-- Despite high prevalence of symptoms, rate of gastroparesis diagnosis is low among those with type 2 diabetes -- BOSTON, May 20, 2013 /PRNewswire/ -- Rhythm announced today the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms among diabetic patients in the U.S. than previously recognized. Prevalence of these symptoms is high among patients with both type 1 and type 2 diabetes, but this condition is significantly...

SAN DIEGO, May 20, 2013 /PRNewswire/ -- Enrollment of patients with Type 2 diabetes is underway in Elcelyx Therapeutics' Phase 2b dose-finding clinical trial of product candidate NewMet(TM), a delayed-release formulation of generic metformin, the foundational treatment for Type 2 diabetes. Elcelyx expects to complete enrollment of 240 patients in the multicenter U.S. program in June. Results of the trial's primary endpoint of change in fasting plasma glucose are expected in late...